Figure 4.

The effect of the vascular disrupting agent azademethylcolchicine (ICT2552) conjugated with the cross-linked iron oxide nanoparticle CLIO-ICT, in combination with radiation therapy, was monitored by MRI. (A) Representative coronal T2-weighted MR images of the brain of NSG™ mice with GBM39 glioblastoma tumors, before and after CLIO-ICT (10 mg/kg ICT, 34 mg/kg Fe) and/or radiation (10 Gy) treatment (as monitored at 24 h and on 14 days). Hypointense tumor enhancement in animals treated with CLIO-ICT and CLIO-ICT + radiation confirms theranostic nanoparticle delivery. Corresponding T2 relaxation times of tumors (B) and normal brain (C), before and 24 h after therapy. *** p < 0.001, ns = not significant. Figure reproduced from ref. [35].